VIVUS Announces ADA Scientific Presentations

        Print
| Source: VIVUS, Inc.

MOUNTAIN VIEW, Calif., June 21, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today announced the following scientific presentations:

Conference

ADA 2013: American Diabetes Association 73rd Scientific Sessions

June 21-25, 2013

McCormick Place Convention Center (West Building), Chicago, IL

Date/Time

Poster Presentation Date: Sunday, June 23th, 2013 from 12:00 to 2:00 PM

Session Location: Poster Hall, McCormick Place Convention Center

Poster Number: 2133-P

Presentation Title

Contributions of Percent and Absolute Weight Loss to Improvements in Fasting Glucose and Insulin Sensitivity

Authors: W. Timothy Garvey, MDa; Wesley W. Day, PhDb

Affiliations: aUniversity of Alabama at Birmingham, Birmingham, AL; bVIVUS, Inc., Mountain View, CA

Conference

ADA 2013: American Diabetes Association 73rd Scientific Sessions

June 21-25, 2013

McCormick Place Convention Center (West Building), Chicago, IL

Date/Time

Guided Poster Presentation Tour: Saturday, June 22nd, 2013 from 11:30 AM 12:30 PM

Poster Presentation Date: Sunday, June 23th, 2013 from 12:00 to 2:00 PM

Session Location: Poster Hall, McCormick Place Convention Center

Poster Number: 2103-P

Presentation Title

Weight Loss With Phentermine and Topiramate Extended-Release and Changes in Glycemic Parameters in Overweight and Obese Adults With Dysglycemia and Stratified by Baseline Body-Mass Index

Authors: Donna H. Ryan, MDa; Charles H. Bowden, MDb

Affiliations: aPennington Biomedical Research Center, Baton Rouge, Louisiana; bVIVUS, Inc., Mountain View, California

Conference

ADA 2013: American Diabetes Association 73rd Scientific Sessions

June 21-25, 2013

McCormick Place Convention Center (West Building), Chicago, IL

Date/Time

Poster Presentation Date: Sunday, June 23th, 2013 from 12:00 to 2:00 PM

Session Location: Poster Hall, McCormick Place Convention Center

Poster Number: 2121-P

Presentation Title

Changes in Glycemic Parameters and Antidiabetic Medication Use by Degree of Weight Loss With Lifestyle Modification and Phentermine/Topiramate Extended-Release

Authors: Robert Kushner, MDa; Barbara Troupin, MDb

Affiliations: aNorthwestern University Feinberg School of Medicine, Chicago, Illinois; bVIVUS, Inc., Mountain View, California

About Qsymia

Qsymia® (phentermine and topiramate extended-release) capsules CIV is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.

The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.

Important Safety Information

Qsymia® (phentermine and topiramate extended-release) capsules CIV is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in Qsymia.

Qsymia can cause fetal harm. Females of reproductive potential should have a negative pregnancy test before treatment and monthly thereafter and use effective contraception consistently during Qsymia therapy. If a patient becomes pregnant while taking Qsymia, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.

The most commonly observed side effects in controlled clinical studies, 5% or greater and at least 1.5 times placebo, include paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth.

About VIVUS

VIVUS is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS's Form 10-K for the year ending December 31, 2012, as amended by the Form 10-K/A filed on April 30, 2013 and by the Form 10-K/A filed on June 12, 2013, and periodic reports filed with the Securities and Exchange Commission.

VIVUS, Inc.
Dana B. Shinbaum
Corporate Development
& Investor Relations


Investor Relations:
The Trout Group
Brian Korb

646-378-2923